20:56 , Mar 8, 2019 |  BioCentury  |  Emerging Company Profile

Synbal: Gene driving on parallel tracks

Synbal is tapping new genetic approaches to develop both rodents with humanized metabolisms and cell therapies for lysosomal storage diseases. Ethan Bier, Valentino Gantz and Tsvi Goldenberg spun out Synbal Inc. from the University of...
22:27 , Feb 2, 2018 |  BioCentury  |  Finance

Building momentum

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates. Cormorant Asset Management and...
13:13 , Feb 1, 2018 |  BC Extra  |  Financial News

Cell therapy play Avrobio raises $60M

Avrobio Inc. (Cambridge, Mass.) raised $60 million in a series B round co-led by Cormorant Asset Management and Surveyor Capital. Fellow new investors Aisling, Brace Pharma Capital, Eventide, Morningside and Leerink Partners also participated alongside...